Hoth Therapeutics shares surged more than 55% pre-market after the company announced positive data from its HT-VA study evaluating parenteral GDNF. The update appears to be a meaningful clinical readout for the biotech, supporting a sharply positive market reaction. Despite the strong move, the news is company-specific rather than sector-wide.
Hoth Therapeutics shares surged more than 55% pre-market after the company announced positive data from its HT-VA study evaluating parenteral GDNF. The update appears to be a meaningful clinical readout for the biotech, supporting a sharply positive market reaction. Despite the strong move, the news is company-specific rather than sector-wide.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.70
Ticker Sentiment
